IMEL co-founded byDr. Silvia Noiman, Pontifax &Mr. Taro Inaba, Remiges

Treatment based on a novel,proprietary, understandingof mitochondrial biology

IMELin anutshell

Technology invented
by Dr. Gojo of Kyoto
Prefectural University,
Japan and the IP
assigned to IMELIMEL develops a new paradigm
for the treatment of patientswith mitochondrial dysfunction

Targeting multiple
mitochondrial
dysfunction related
indications

Multi-billion dollars
markets with unmet need

Maeda et al. Scientific Reports 2020; 10 (1): 1-10; Maeda et al. Scientific Reports, 2021; 11(1): 1-16Mitochondrial
dysfunction mechanism

Mitochondrial
dysfunction indications

Mitochondrial dysfunction occurred due togenetic or acquired processes

Mitochondrial
diseases

Mutation(s) in mitochondrial DNA (mtDNA)
or reduction in mtDNA copy levels are
inherited or result from increased oxidative
stress in patients>100 genetic disorders
are characterized by
defective oxidative
phosphorylation

Aging processes include altered mitochondrial
dynamics & protein synthesis, mitophagy,
reactive oxygen species and mtDNA damage

Multisystemic disease
presentations

Leigh syndrome

Functional

Genetic
dysfunction

MELAS
LHON
cPEOMERRF
KSS

TK2

NARP

Acquireddysfunction

MNGIE

Luft Disease

Bath Syndrome

Friedreich’s Ataxia

Aging related indications
Mitochondrial dysfunction
is one of the cellular andmolecular hallmarks ofaging
Mitochondrial dysfunction
is driving the dysregulationof the immune system
during aging and cancer
Alzheimer’s disease

Immunosenescence

Pulmonary fibrosis
Chronic kidneydisease (CKD)

Chronic obstructive
pulmonary disease(COPD)
Metabolic disease

Cardiovasculardisease

Liver disease

IMEL’s breakthroughtechnology
We develop cell-based mitochondria
rescue therapy to treat all mitochondrial
dysfunction
We use novel biological insight tochange the proportion of healthy todysfunctional mitochondria within cellsof the target tissues
We replace the "dead batteries" of thecell to restart cell & tissue functionality

Dysfunctional

Functional

IMEL’s products:
Autologous mitochondrial
replaced cells (MirC) forcell-based therapy
0601

Monitorsubject
recoveryCollect blood
cells via
apheresis

05

02

InfuseMitochondria
replacedproductSelecttarget cells

0403

Prepare cellbased productfor treatment

Replace targetcells withhealthy donor
mitochondriaInvestors and Directors

Pontifax is a venture
capital firm focusing
on groundbreaking
innovations in life
sciences

Remiges is a USJapanese venture
capital firm focusedon biotechnology
and pharmaceuticalcompanies

Korea Investment
Partners Co. (KIP) is
South Korea’s largest
venture capital firmmanages total of$3B in assets

Consensus BusinessGroup (CBG) is a UKbased investmentgroup, led byTchenguiz family

Founded in 2004,
Pontifax manages
over $1.2B witha portfolio 100
companies

Founded in2014, Remiges
is developing IP
from the Japanese
academiaFounded in 1986,
KIP strategy is tofoster startups togrow into middlemarket companies
through IPOs

CBG investment
portfolio > $700M intechnologies, funds,incubators, andother initiatives

Suite 300, 303 Wyman St., Waltham, MA 02451
Contact info: Dori Pelled, Ph.D - COO+972 5 4450 6092

dori@imelbiotx.com